Table 1:
Demographic Breakdown of E-diary and vEEG Cohorts
| E-diary Cohort (N = 314) | E-diary Subset Under 1 Year (N = 86) |
vEEG Cohort (N = 9) | |
|---|---|---|---|
| Factor | n (%) | n (%) | n (%) |
| Sex | |||
| Female | 162 (51.6) | 41 (47.7) | 5 (51.6) |
| Male | 146 (46.5) | 45 (52.3) | 4 (44.4) |
| Undisclosed | 6 (1.9) | 0 (0) | 0 (0) |
| Age of onseta (years) | 2.8 [0.9-12.4] | 0.52 [0.40-0.75] | 0.6 [0.51-0.88] |
| Underlying Condition | |||
| Congenital Syndrome | 119 (37.9) | 36 (41.9) | 2 (22.2) |
| Other | 45 (14.3) | 10 (11.6) | 1 (11.1) |
| Tuberous Sclerosis | 30 (9.6) | 14 (16.3) | 0 (0) |
| Lennox-Gastaut | 13 (4.1) | 0 (0) | 1 (11.1) |
| Aicardi | 18 (5.7) | 9 (10.5) | 0 (0) |
| Rett | 4 (1.3) | 0 (0) | 0 (0) |
| Dravet | 3 (1.0) | 0 (0) | 0 (0) |
| Down | 2 (0.6) | 2 (2.3) | 0 (0) |
| Phelan-McDermid | 1 (0.3) | 0 (0) | 0 (0) |
| Hypothalamic Hamartoma | 1 (0.3) | 0 (0) | 0 (0) |
| Angelman Syndrome | 1 (0.3) | 0 (0) | 0 (0) |
| Sturge-Weber | 1 (0.3) | 1 (1.2) | 0 (0) |
| Stroke | 9 (2.9) | 4 (4.7) | 3 (33.3) |
| Metabolic Disorder | 5 (1.6) | 0 (0) | 0 (0) |
| Infection | 12 (3.8) | 1 (1.2) | 0 (0) |
| Perinatal Hypoxia | 7 (2.2) | 2 (2.3) | 3 (33.3) |
| Maternal Drug Abuse | 4 (1.3) | 0 (0) | 0 (0) |
| Brain Malformations | 39 (12.4) | 18 (20.9) | 0 (0) |
| Brain Trauma | 25 (8.0) | 6 (7.0) | 0 (0) |
| Electrolyte Disturbance | 1 (0.3) | 0 (0) | 0 (0) |
| Medication Usage b,c | |||
| Unique Meds per Childa | 2 [0-3] | 2 [0-3] | 0 [0-1] |
| Levetiracetam | 83 (26.4) | 24 (27.9) | 2 (22.2) |
| Topiramate | 59 (18.8) | 22 (25.6) | 0 (0) |
| Vigabatrin | 56 (17.8) | 30 (34.9) | 1 (11.1) |
| Valproic acid | 48 (15.3) | 5 (5.8) | 0 (0) |
| Clobazam | 48 (15.3) | 9 (10.5) | 0 (0) |
| Lamotrigine | 40 (12.7) | 1 (1.2) | 0 (0) |
a
These data are depicted as median [IQR]
b
These are the top six most commonly reported meds in the e-diary cohort
c
vEEG cohort data consists of neuroactive medications at time of epileptic spasms diagnosis